Trials / Completed
CompletedNCT01516424
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone
A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 267 (actual)
- Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone
Detailed description
A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone Trial drugs: * Blonanserin group: Blonanserin tablets+Risperidone mimetic tablets * Risperidone group: Risperidone tablets+Blonanserin mimetic tablets Objectives of Study : To evaluate the efficacy and safety of Blonanserin in treating schizophrenia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blonanserin | Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days. |
| DRUG | Risperidone | Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days. |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2012-01-24
- Last updated
- 2018-11-27
- Results posted
- 2018-11-26
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01516424. Inclusion in this directory is not an endorsement.